Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LLY · NYSE · Pharmaceuticals
Eli Lilly (LLY) · oqro.io/stocks/LLY · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
No open-market purchase by an insider of Eli Lilly was filed in the last 90 days. The latest on record was on Aug 15, 2025.
Since 2006, Eli Lilly insiders reported 35 open-market purchases and 6,839 sales on Forms 4 and 5, with purchases in 8 different years, most recently 2025.
In the last 90 days, 1 insider of Eli Lilly (LLY) reported 1 open-market sale worth $7.01M in total on SEC Form 4. The largest seller by value was Anat Hakim, with $7.01M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 26 trades in Eli Lilly (LLY) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. David J. Taylor (OH02), Rep. Gilbert Ray Cisneros Jr. (CA31), Rep. Michael A. Rulli (OH06) and 8 other members.
Eli Lilly's next results are expected on Feb 2, 2027, before the market opens. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1,382.75−32.80 (−2.32%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+34.2% (+$352.70) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $1,030.05 on Nov 18, 2025 to $1,382.75 on Nov 18, 2026 (+34.2%). Disclosed in this range: 114 insider trades, 5 pre-arranged insider sales, 25 Congress trades, and 552 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Diabetes, obesity and cancer medicines.
Last 12 months
+34.2%
Market value
$1.3T
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 7.21M shares sold short (0.8% of shares outstanding), +3.6% vs the previous count, 2.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Eli Lilly: 1 fund cut or exited a position in the latest available 13F filings and 1 member of Congress disclosed sales. 2 of 3 tracked groups show selling activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Eli Lilly: 1 fund opened or increased a position in the latest available 13F filings and 1 member of Congress disclosed purchases. 2 of 3 tracked groups show buying activity. Based on public disclosures; it does not say why, or what happens next. Our test of this pattern
Revenue
$24.4B
+38.6% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
$44.6B
Debt $49.5B, cash $4.88B, at Sep 30, 2026
Net income, last 12 months
$27.6B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 29, 2026.
Revenue, fiscal 2025
$65.2B
+44.7% vs the year before
Net income, fiscal 2025
$20.6B
As reported in the annual filing
Shares outstanding
941M
As of Oct 26, 2026
In fiscal 2025 the company spent $4.11B buying back its own shares and $5.38B on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
2 tracked managers disclosed the same change for Q3 2026. From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
2 tracked managers disclosed the same change for Q3 2026. From a 13F filed Nov 13, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Traded Nov 3, 2026 · disclosed 9 days later
Nov 3, 2026$1,001–$15,000
DetailsOfficial recordNov 3, 2026$1,001–$15,000
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for Eli Lilly over the 12 months to Nov 19, 2026: 14 FDA records, 6 executive contributions and 145 clinical trials (3rd most among listed companies).
Written by software from the filings listed below · Nov 13, 2026
4 more points, with the facts they come from, are in OQRO Pro.
Sign up freeInsiders of Eli Lilly reported 35 open-market purchases and 6,839 sales since 2006; purchases in 8 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $365M38×38 trades |
| 2025 | $4.54M9×9 trades | $4.22B441×441 trades |
| 2024 | — | $2.35B245×245 trades |
| 2023 | — | $22B179×179 trades |
| 2022 | $249K2×2 trades | $1.4B170×170 trades |
| 2021 | $250K2×2 trades | $855M113×113 trades |
| 2020 | — | $531M78×78 trades |
| 2019 | $1.52M7×7 trades | $438M61×61 trades |
| 2018 | $1.22M3×3 trades | $521M73×73 trades |
| 2017 | — | $219M28×28 trades |
| 2016 | $1.14M8×8 trades | $184M38×38 trades |
| 2015 | — | $304M42×42 trades |
| 2014 | $1.02M3×3 trades | $290M42×42 trades |
| 2013 | — | $6.68M14×14 trades |
| 2012 | — | $3.09M14×14 trades |
| 2011 | — | $6.49M32×32 trades |
| 2010 | — | $1.22M20×20 trades |
| 2009 | — | $98K1×1 trade |
| 2008 | $1M1×1 trade | $88.7M1584×1,584 trades |
| 2007 | — | $168M885×885 trades |
| 2006 | — | $404M2741×2,741 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
LILLY ENDOWMENT, INC.
Schedule 13G: passive · filed Oct 19, 2026 · 90.1M shares
Vanguard Capital Management
Schedule 13G: passive · filed May 1, 2026 · 61.3M shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Against the S&P 500 over the year
Since Nov 14, 2025, LLY is up 38.1% and the index fund is up 9.0%: 29 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much LLY moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Short sale volume: 35.6% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 39.2%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 2,847 shares (about $3.65M) were not delivered on time for settlement on Oct 21, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
16 approvals or clearances and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last results
Oct 29, 2026
Within the 30 days after it, until Nov 28, 2026
Next results, expected
Feb 2, 2027
before the market opens; the date can move until the company confirms it
Purchases after results
100%
11 of 11 insider purchases since 2021 came within 30 days after a results announcement
From Eli Lilly's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Eli Lilly's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
132 certified in FY2026 Q3, vs 310 a year earlier. 475 positions in total, median offered wage $136K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
94 active phase 3 trials and 51 active phase 2 trials led by this company, mostly in obesity, breast neoplasms, alzheimer disease. The ones with the nearest registered primary completion date still ahead:
36 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.